18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors.
FDG PET
immune checkpoint inhibitors
immunotherapy
melanoma
therapeutic response
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Jun 2022
29 Jun 2022
Historique:
received:
31
05
2022
revised:
20
06
2022
accepted:
22
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
10
7
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICI) are currently the first-line treatment for patients with metastatic melanoma. We investigated the value of positron emission tomography (PET) response criteria to assess the therapeutic response to first-line ICI in this clinical context and explore the potential contribution of total tumor metabolic volume (TMTV) analysis. We conducted a retrospective study in patients treated with first-line ICI for advanced or metastatic melanoma, with 18F-FDG PET/CT performed at baseline and 3 months after starting treatment. Patients' metabolic response was classified according to PERCIST5 and imPERCIST 5 criteria. TMTV was recorded for each examination. Twenty-nine patients were included. The median overall survival (OS) was 51.2 months (IQR 13.6-not reached), and the OS rate at 2 years was 58.6%. Patients classified as responders (complete and partial response) had a 90.9% 2-year OS rate versus 38.9% for non-responders (stable disease and progressive disease) ( The evaluation of response to immunotherapy using metabolic imaging with PERCIST5 and imPERCIST5 was significantly associated with OS in patients with advanced or metastatic melanoma.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors (ICI) are currently the first-line treatment for patients with metastatic melanoma. We investigated the value of positron emission tomography (PET) response criteria to assess the therapeutic response to first-line ICI in this clinical context and explore the potential contribution of total tumor metabolic volume (TMTV) analysis.
METHODS
METHODS
We conducted a retrospective study in patients treated with first-line ICI for advanced or metastatic melanoma, with 18F-FDG PET/CT performed at baseline and 3 months after starting treatment. Patients' metabolic response was classified according to PERCIST5 and imPERCIST 5 criteria. TMTV was recorded for each examination.
RESULTS
RESULTS
Twenty-nine patients were included. The median overall survival (OS) was 51.2 months (IQR 13.6-not reached), and the OS rate at 2 years was 58.6%. Patients classified as responders (complete and partial response) had a 90.9% 2-year OS rate versus 38.9% for non-responders (stable disease and progressive disease) (
CONCLUSION
CONCLUSIONS
The evaluation of response to immunotherapy using metabolic imaging with PERCIST5 and imPERCIST5 was significantly associated with OS in patients with advanced or metastatic melanoma.
Identifiants
pubmed: 35804963
pii: cancers14133190
doi: 10.3390/cancers14133190
pmc: PMC9264956
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):930-939
pubmed: 30488098
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2787-2795
pubmed: 32296882
J Nucl Med. 2019 Mar;60(3):335-341
pubmed: 30413661
J Natl Cancer Inst. 2011 Jan 19;103(2):129-42
pubmed: 21081714
Melanoma Res. 2019 Apr;29(2):178-186
pubmed: 30653029
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2776-2786
pubmed: 32338306
Clin Cancer Res. 2020 Aug 15;26(16):4414-4425
pubmed: 32253232
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2298-2310
pubmed: 31346755
Clin Cancer Res. 2015 Nov 15;21(22):4989-91
pubmed: 26567357
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1158-1167
pubmed: 31760467
Clin Nucl Med. 2020 Mar;45(3):187-194
pubmed: 31977479
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
JCO Precis Oncol. 2017 Nov;1:1-14
pubmed: 35172485
EJNMMI Res. 2019 Jan 29;9(1):8
pubmed: 30694399
Cancer Treat Rev. 2017 Sep;59:71-78
pubmed: 28756306
Syst Rev. 2012 Dec 13;1:62
pubmed: 23237499
Eur J Cancer. 2020 Feb;126:159-177
pubmed: 31866016
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296
pubmed: 29478079
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383
pubmed: 29124281
Cancers (Basel). 2021 Jan 06;13(2):
pubmed: 33418936
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Curr Oncol. 2021 Apr 27;28(3):1630-1640
pubmed: 33925392
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):386-96
pubmed: 25359635
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835
Medicine (Baltimore). 2019 Jul;98(29):e16417
pubmed: 31335691
Eur J Radiol. 2022 Jan;146:110107
pubmed: 34922117